This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/drug/DB09015/identifier/wikipedia/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB09015/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB09015/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://www.drugs.com/international/
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB09015
rdf:type
n3:Drug
n3:description
Potassium canrenoate, the potassium salt of canrenoic acid, is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.
n3:group
withdrawn approved
owl:sameAs
n15:DB09015
dcterms:title
Potassium Canrenoate
adms:identifier
n8:D01943 n9:Potassium_canrenoate n10:DB09015
n3:synthesisReference
U.S. Patent 2,900,383.
foaf:page
n13:potassium-canrenoate.html
n3:IUPAC-Name
n4:271B64EF-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B64F5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B64F4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B64F1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B64F2-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B64F3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B64ED-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B64EE-363D-11E5-9242-09173F13E4C5 n4:271B64EB-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B64EC-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:C03DA02
n3:H-Bond-Acceptor-Count
n4:271B64FB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B64FC-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B64F6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B64F7-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B64F9-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B64F8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B64FA-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
2181-04-6
n3:Bioavailability
n4:271B6501-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6503-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6504-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6505-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6500-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B64FF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6502-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B64F0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B64FD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B64FE-363D-11E5-9242-09173F13E4C5